ReviewWorld journal of oncology2021
An Update on Survivorship Issues in Lung Cancer Patients.
Review in World journal of oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- The effects of tislelizumab treatment on the health-related quality of life of patients with advanced non-small cell lung cancer.Cancer medicine · 2023Trial
- Bringing lung cancer above ground through storytelling: Creating a lung cancer advocacy network.PEC innovation · 2026Article
- Article
- Health-Related Quality of Life in Lung Cancer Survivors: Sociodemographic, Clinical, and Psychosocial Modulators.Current oncology (Toronto, Ont.) · 2026Article
- Comparison of Surveillance with Low-Dose and Contrast-Enhanced Chest Computed Tomography in Patients Disease-Free for 2 Years after Curative Resection for Lung Cancer.Cancer research and treatment · 2026Article
- Fear of cancer recurrence mediates the association between symptom burden and readiness for return to work in patients with lung cancer.Asia-Pacific journal of oncology nursing · 2025Article
- Prediction of medication nonadherence in patients with lung cancer based on nomogram model construction.Medicine · 2025Observational
- Mediators of Racial Inequities in Non-Small Cell Lung Cancer Care.Cancer medicine · 2025Article
- Contemporaneous symptom networks for multidimensional symptom experience in lung cancer survivors of immunotherapy: A network analysis.PloS one · 2025Article
- Receipt of follow-up care plans on colorectal cancer screening among breast, prostate, and lung cancer survivors.Journal of cancer survivorship : research and practice · 2024Article
- Influence of initial check, information exchange, final accuracy check, reaction information nursing on the psychology of elderly with lung cancer.World journal of clinical cases · 2024Article
- The cerebral metabolic mechanism of group computer magnanimous therapy based on magnetic resonance spectroscopy: effects on improving magnanimous-enterprising levels of lung cancer patients.Frontiers in psychiatry · 2024Article
- An eHealth ecosystem for stepped and early psychosocial care in advanced lung cancer: Rationale and protocol for a randomized control trial.Internet interventions · 2023Article
- What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?Therapeutic advances in medical oncology · 2023Review
- Self-efficacy and positive coping mediate the relationship between social support and resilience in patients undergoing lung cancer treatment: A cross-sectional study.Frontiers in psychology · 2022Article
- MicroRNA-106a regulates autophagy-related cell death and EMT by targeting TP53INP1 in lung cancer with bone metastasis.Cell death & disease · 2021Article
- Early, integrated palliative care for people with chronic respiratory disease: lessons learnt from lung cancer.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in lung cancer therapeutics and screening have led to increased numbers of lung cancer survivors. Most survivors have undergone invasive treatment (surgery, radiation therapy, chemotherapy and/or immunotherapy) and carry a high comorbidity burden. Overall quality of life suffers during the evaluation, treatment and follow-up phase, with the potential for long-term decline. The issues faced by survivors include physical symptoms, emotional distress as well as socioeconomic instability. These issues may lead to poor compliance with recommended follow-up plan. This article provides an up-to-date literature review on the major issues faced by lung cancer survivors and identifies under-recognized problems such as stigma, financial toxicity and sexual dysfunction. Future collaborative efforts are needed to further elucidate the complex issues that affect overall well-being of lung cancer survivors and to develop appropriate interventions in this expanding survivor population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.